Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 8/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28631346 | 1.00 | CYP2D6 (0.48) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL15627223 | 1.00 | CYP2D6 (0.48) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL23314770 | 0.84 | CTSK (0.47) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL15629776 | 0.84 | CTSK (0.61) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL6381798 | 0.84 | CTSK (0.52) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL30993196 | 0.81 | CA1 (0.49) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL30993172 | 0.81 | CA1 (0.49) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL31606449 | 0.80 | CYP2D6 (0.53) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL13538162 | 0.80 | CYP2D6 (0.53) | CYP2D6CTSKCA1CA2CA7 | |
| SCHEMBL14931110 | 0.80 | CYP2D6 (0.53) | CYP2D6CTSKCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661084-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | CYP2D6 4186/4885CTSK 343/4885CA1 3613/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | CYP2D6 3451/4885CTSK 228/4885CA1 4337/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CYP2D6 3451/4885CTSK 228/4885CA1 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.